Related Experiment Videos
[Androgens and other hormones in buserelin therapy]
Geburtshilfe Und Frauenheilkunde
|February 1, 1991
Summary
Buserelin nasal spray effectively treated endometriosis in women by reducing key hormones like LH and E2. This hormonal therapy led to a significant decrease in endometriosis implants after six months.
Area of Science:
- Reproductive Endocrinology
- Gynecological Oncology
Context:
- Endometriosis affects women of reproductive age.
- Laparoscopic and bioptic methods diagnose endometriosis.
- Hormonal imbalances are implicated in endometriosis progression.
Purpose:
- To evaluate the efficacy of Buserelin nasal spray in treating endometriosis.
- To assess the hormonal changes induced by Buserelin therapy.
- To determine the impact of Buserelin on endometriosis lesion scores.
Summary:
- Twenty-three women with diagnosed endometriosis received Buserelin nasal spray for six months.
- Serum hormone levels (LH, E2, prolactin, progesterone, testosterone) significantly decreased.
- FSH, free testosterone, and androstenedione showed slight decreases; DHEAS and SHBG remained unchanged.
- Buserelin demonstrated no androgenic effects.
- A significant reduction in endometriosis, measured by implantation score, was observed.
Impact:
- Buserelin nasal spray offers a potential therapeutic option for endometriosis.
- Understanding Buserelin's hormonal effects provides insights into endometriosis management.
- The study highlights the link between hormonal modulation and endometriosis regression.